The group's principal activity is the preparation of integrated pharmaceuticals. The group operates in two business segments: manufacturing and radiopharmaceuticals. The manufacturing segment provides contract pharmaceutical manufacturing services through its subsidiary draxis pharma inc. The radiopharmaceutical segment produces and distributes specialized radiopharmaceutical products for both diagnostic and therapeutic applications. The operations of group are carried out in the United States and other countries. Manufacturing accounted for 62% of 2001 revenues; radiopharmaceutical, 21% and corporate and other, 17%.
